PTEN in DNA damage repair

Cancer Letters

Volumn 319, Issue 2, 2012, Pages 125-129

  Ming, Mei ^a   He, Yu Ying ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

DNA damage; DNA repair; PTEN

Indexed keywords

CHECKPOINT KINASE 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RAPAMYCIN;

CANCER PREVENTION; CANCER THERAPY; CELL NUCLEUS; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; GENE DELETION; GENOMIC INSTABILITY; HUMAN; LOSS OF FUNCTION MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RADIOSENSITIVITY; SHORT SURVEY; TRANSCRIPTION REGULATION; ULTRAVIOLET RADIATION;

EID: 84862815940     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.003     Document Type: Review

References (93)

1. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
2. Friedberg E.C. DNA damage and repair. Nature 2003, 421:436-440.
3. Cline S.D., Hanawalt P.C. Who's on first in the cellular response to DNA damage?. Nat. Rev. Mol. Cell. Biol. 2003, 4:361-372.
4. Branzei D., Foiani M. Regulation of DNA repair throughout the cell cycle. Nat. Rev. Mol. Cell. Biol. 2008, 9:297-308.
5. Seviour E.G., Lin S.Y. The DNA damage response: balancing the scale between cancer and ageing. Aging (Albany NY) 2010, 2:900-907.
6. Cleaver J.E., Lam E.T., Revet I. Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. Nat. Rev. Genet. 2009, 10:756-768.
7. Cleaver J.E. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat. Rev. Cancer 2005, 5:564-573.
8. Kraemer K.H., Lee M.M., Scotto J. DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum. Carcinogenesis 1984, 5:511-514.
9. Kraemer K.H., Lee M.M., Andrews A.D., Lambert W.C. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch. Dermatol. 1994, 130:1018-1021.
10. Sugasawa K., Ng J.M., Masutani C., Iwai S., van der Spek P.J., Eker A.P., Hanaoka F., Bootsma D., Hoeijmakers J.H. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol. Cell. 1998, 2:223-232.
11. Sugasawa K. UV-induced ubiquitylation of XPC complex, the UV-DDB-ubiquitin ligase complex, and DNA repair. J. Mol. Histol. 2006, 37:189-202.
12. Niggli H.J., Rothlisberger R. Cyclobutane-type pyrimidine photodimer formation and induction of ornithine decarboxylase in human skin fibroblasts after UV irradiation. J. Invest. Dermatol. 1988, 91:579-584.
13. Vink A.A., Berg R.J., de Gruijl F.R., Roza L., Baan R.A. Induction, repair and accumulation of thymine dimers in the skin of UV-B-irradiated hairless mice. Carcinogenesis 1991, 12:861-864.
14. Cimprich K.A., Cortez D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell. Biol. 2008, 9:616-627.
15. Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.
16. Brown E.J., Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes. Dev. 2003, 17:615-628.
17. Liu Q., Guntuku S., Cui X.S., Matsuoka S., Cortez D., Tamai K., Luo G., Carattini-Rivera S., DeMayo F., Bradley A., Donehower L.A., Elledge S.J. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes. Dev. 2000, 14:1448-1459.
18. Matsuoka S., Huang M., Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998, 282:1893-1897.
19. Chaturvedi P., Eng W.K., Zhu Y., Mattern M.R., Mishra R., Hurle M.R., Zhang X., Annan R.S., Lu Q., Faucette L.F., Scott G.F., Li X., Carr S.A., Johnson R.K., Winkler J.D., Zhou B.B. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999, 18:4047-4054.
20. Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. USA 2000, 97:10389-10394.
21. Ahn J.Y., Schwarz J.K., Piwnica-Worms H., Canman C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 2000, 60:5934-5936.
22. Chehab N.H., Malikzay A., Appel M., Halazonetis T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes. Dev. 2000, 14:278-288.
23. Shieh S.Y., Ahn J., Tamai K., Taya Y., Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes. Dev. 2000, 14:289-300.
24. Ou Y.H., Chung P.H., Sun T.P., Shieh S.Y. P53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation. Mol. Biol. Cell. 2005, 16:1684-1695.
25. Yoon K., Smart R.C. C/EBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes. Mol. Cell. Biol. 2004, 24:10650-10660.
26. Burma S., Chen B.P., Murphy M., Kurimasa A., Chen D.J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J. Biol. Chem. 2001, 276:42462-42467.
27. Kinner A., Wu W., Staudt C., Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 2008, 36:5678-5694.
28. van Attikum H., Gasser S.M. The histone code at DNA breaks: a guide to repair?. Nat. Rev. Mol. Cell. Biol. 2005, 6:757-765.
29. Yang J., Yu Y., Hamrick H.E., Duerksen-Hughes P.J. ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis 2003, 24:1571-1580.
30. Marti T.M., Hefner E., Feeney L., Natale V., Cleaver J.E. H2AX phosphorylation within the G1 phase after UV irradiation depends on nucleotide excision repair and not DNA double-strand breaks. Proc. Natl. Acad. Sci. USA 2006, 103:9891-9896.
31. Hanasoge S., Ljungman M. H2AX phosphorylation after UV irradiation is triggered by DNA repair intermediates and is mediated by the ATR kinase. Carcinogenesis 2007, 28:2298-2304.
32. Barnes L., Dumas M., Juan M., Noblesse E., Tesniere A., Schnebert S., Guillot B., Moles J.P. GammaH2AX, an accurate marker that analyzes UV genotoxic effects on human keratinocytes and on human skin. Photochem. Photobiol. 2010, 86:933-941.
33. Brown E.J., Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes. Dev. 2000, 14:397-402.
34. Menoyo A., Alazzouzi H., Espin E., Armengol M., Yamamoto H., Schwartz S. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res. 2001, 61:7727-7730.
35. Swift M., Reitnauer P.J., Morrell D., Chase C.L. Breast and other cancers in families with ataxia-telangiectasia. N Engl. J. Med. 1987, 316:1289-1294.
36. Renwick A., Thompson D., Seal S., Kelly P., Chagtai T., Ahmed M., North B., Jayatilake H., Barfoot R., Spanova K., McGuffog L., Evans D.G., Eccles D., Easton D.F., Stratton M.R., Rahman N. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 2006, 38:873-875.
37. Hannan M.A., Hellani A., Al-Khodairy F.M., Kunhi M., Siddiqui Y., Al-Yussef N., Pangue-Cruz N., Siewertsen M., Al-Ahdal M.N., Aboussekhra A. Deficiency in the repair of UV-induced DNA damage in human skin fibroblasts compromised for the ATM gene. Carcinogenesis 2002, 23:1617-1624.
38. Hirao A., Cheung A., Duncan G., Girard P.M., Elia A.J., Wakeham A., Okada H., Sarkissian T., Wong J.A., Sakai T., De Stanchina E., Bristow R.G., Suda T., Lowe S.W., Jeggo P.A., Elledge S.J., Mak T.W. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol. Cell. Biol. 2002, 22:6521-6532.
39. Kuhne M., Riballo E., Rief N., Rothkamm K., Jeggo P.A., Lobrich M. A double-strand break repair defect in ATM-deficient cells contributes to radiosensitivity. Cancer Res. 2004, 64:500-508.
40. Shell S.M., Li Z., Shkriabai N., Kvaratskhelia M., Brosey C., Serrano M.A., Chazin W.J., Musich P.R., Zou Y. Checkpoint kinase ATR promotes nucleotide excision repair of UV-induced DNA damage via physical interaction with xeroderma pigmentosum group A. J. Biol. Chem. 2009, 284:24213-24222.
41. Di Cristofano A., Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 2000, 100:387-390.
42. Keniry M., Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008, 27:5477-5485.
43. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P.P. PTEN is essential for embryonic development and tumour suppression. Nat. Genet. 1998, 19:348-355.
44. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1998, 273:13375-13378.
45. Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc. Natl. Acad. Sci. USA 1998, 95:13513-13518.
46. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
47. Carracedo A., Pandolfi P.P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008, 27:5527-5541.
48. Liaw D., Marsh D.J., Li J., Dahia P.L., Wang S.I., Zheng Z., Bose S., Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 1997, 16:64-67.
49. Marsh D.J., Dahia P.L., Zheng Z., Liaw D., Parsons R., Gorlin R.J., Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat. Genet. 1997, 16:333-334.
50. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., del Barco Barrantes I., Ho A., Wakeham A., Itie A., Khoo W., Fukumoto M., Mak T.W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 1998, 8:1169-1178.
51. Zhou X.P., Marsh D.J., Hampel H., Mulliken J.B., Gimm O., Eng C. Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum. Mol. Genet. 2000, 9:765-768.
52. Zhou X., Hampel H., Thiele H., Gorlin R.J., Hennekam R.C., Parisi M., Winter R.M., Eng C. Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 2001, 358:210-211.
53. Ming M., Feng L., Shea C.R., Soltani K., Zhao B., Han W., Smart R.C., Trempus C.S., He Y.Y. PTEN positively regulates UVB-induced DNA damage repair. Cancer Res. 2011, 71:5287-5295.
54. Backman S.A., Ghazarian D., So K., Sanchez O., Wagner K.U., Hennighausen L., Suzuki A., Tsao M.S., Chapman W.B., Stambolic V., Mak T.W. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of PTEN. Proc. Natl. Acad. Sci. USA 2004, 101:1725-1730.
55. Li G., Robinson G.W., Lesche R., Martinez-Diaz H., Jiang Z., Rozengurt N., Wagner K.U., Wu D.C., Lane T.F., Liu X., Hennighausen L., Wu H. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002, 129:4159-4170.
56. Suzuki A., Itami S., Ohishi M., Hamada K., Inoue T., Komazawa N., Senoo H., Sasaki T., Takeda J., Manabe M., Mak T.W., Nakano T. Keratinocyte-specific PTEN deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res. 2003, 63:674-681.
57. Yanagi S., Kishimoto H., Kawahara K., Sasaki T., Sasaki M., Nishio M., Yajima N., Hamada K., Horie Y., Kubo H., Whitsett J.A., Mak T.W., Nakano T., Nakazato M., Suzuki A. Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. J. Clin. Invest. 2007, 117:2929-2940.
58. Ming M., Shea C.R., Feng L., Soltani K., He Y.Y. UVA induces lesions resembling seborrheic keratoses in mice with keratinocyte-specific PTEN downregulation. J. Invest. Dermatol. 2011, 131:1583-1586.
59. Ming M., He Y.Y. PTEN: new insights into its regulation and function in skin cancer. J. Invest. Dermatol. 2009, 129:2109-2112.
60. Shen W.H., Balajee A.S., Wang J., Wu H., Eng C., Pandolfi P.P., Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170.
61. Rosser C.J., Tanaka M., Pisters L.L., Tanaka N., Levy L.B., Hoover D.C., Grossman H.B., McDonnell T.J., Kuban D.A., Meyn R.E. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene. Ther. 2004, 11:273-279.
62. Pappas G., Zumstein L.A., Munshi A., Hobbs M., Meyn R.E. Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene. Ther. 2007, 14:543-549.
63. Gupta A., Yang Q., Pandita R.K., Hunt C.R., Xiang T., Misri S., Zeng S., Pagan J., Jeffery J., Puc J., Kumar R., Feng Z., Powell S.N., Bhat A., Yaguchi T., Wadhwa R., Kaul S.C., Parsons R., Khanna K.K., Pandita T.K. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 2009, 8:2198-2210.
64. Puc J., Parsons R. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle 2005, 4:927-929.
65. Ming M., Shea C.R., Guo X., Li X., Soltani K., Han W., He Y.Y. Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C. Proc. Natl. Acad. Sci. USA 2010, 107:22623-22628.
66. Lian Z., Di Cristofano A. Class reunion: PTEN joins the nuclear crew. Oncogene 2005, 24:7394-7400.
67. Chang C.J., Mulholland D.J., Valamehr B., Mosessian S., Sellers W.R., Wu H. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol. Cell. Biol. 2008, 28:3281-3289.
68. Chung J.H., Ostrowski M.C., Romigh T., Minaguchi T., Waite K.A., Eng C. The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Hum. Mol. Genet. 2006, 15:2553-2559.
69. Gil A., Andres-Pons A., Fernandez E., Valiente M., Torres J., Cervera J., Pulido R. Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol. Biol. Cell. 2006, 17:4002-4013.
70. Liu J.L., Sheng X., Hortobagyi Z.K., Mao Z., Gallick G.E., Yung W.K. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol. Cell. Biol. 2005, 25:6211-6224.
71. Planchon S.M., Waite K.A., Eng C. The nuclear affairs of PTEN. J. Cell. Sci. 2008, 121:249-253.
72. Chung J.H., Ginn-Pease M.E., Eng C. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res. 2005, 65:4108-4116.
73. Liu J.L., Mao Z., LaFortune T.A., Alonso M.M., Gallick G.E., Fueyo J., Yung W.K. Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res. 2007, 67:11054-11063.
74. Zhou X.P., Gimm O., Hampel H., Niemann T., Walker M.J., Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol. 2000, 157:1123-1128.
75. Whiteman D.C., Zhou X.P., Cummings M.C., Pavey S., Hayward N.K., Eng C. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int. J. Cancer 2002, 99:63-67.
76. Gu J., Tamura M., Yamada K.M. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J. Cell. Biol. 1998, 143:1375-1383.
77. Martin S.A., Ouchi T. Cellular commitment to reentry into the cell cycle after stalled DNA is determined by site-specific phosphorylation of Chk1 and PTEN. Mol. Cancer Ther. 2008, 7:2509-2516.
78. Puc J., Keniry M., Li H.S., Pandita T.K., Choudhury A.D., Memeo L., Mansukhani M., Murty V.V., Gaciong Z., Meek S.E., Piwnica-Worms H., Hibshoosh H., Parsons R. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005, 7:193-204.
79. Lee C., Kim J.S., Waldman T. PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells. Cancer Res. 2004, 64:6906-6914.
80. A.M. Bode, Z. Dong, Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci STKE 2003 (2003) RE2.
81. He Y.Y., Huang J.L., Chignell C.F. Delayed and sustained activation of extracellular signal-regulated kinase in human keratinocytes by UVA: implications in carcinogenesis. J. Biol. Chem. 2004, 279:53867-53874.
82. Ali I.U. Gatekeeper for endometrium: the PTEN tumor suppressor gene. J. Natl. Cancer Inst. 2000, 92:861-863.
83. Paez J., Sellers W.R. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat. Res. 2003, 115:145-167.
84. Zhang X.P., Liu F., Wang W. Two-phase dynamics of p53 in the DNA damage response. Proc. Natl. Acad. Sci. USA 2011, 108:8990-8995.
85. Freeman D.J., Li A.G., Wei G., Li H.H., Kertesz N., Lesche R., Whale A.D., Martinez-Diaz H., Rozengurt N., Cardiff R.D., Liu X., Wu H. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003, 3:117-130.
86. Selvendiran K., Tong L., Vishwanath S., Bratasz A., Trigg N.J., Kutala V.K., Hideg K., Kuppusamy P. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J. Biol. Chem. 2007, 282:28609-28618.
87. Kandel E.S., Skeen J., Majewski N., Di Cristofano A., Pandolfi P.P., Feliciano C.S., Gartel A., Hay N. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol. Cell. Biol. 2002, 22:7831-7841.
88. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., Morrison S.J. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006, 441:475-482.
89. Zhang J., Grindley J.C., Yin T., Jayasinghe S., He X.C., Ross J.T., Haug J.S., Rupp D., Porter-Westpfahl K.S., Wiedemann L.M., Wu H., Li L. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006, 441:518-522.
90. Lee J.Y., Nakada D., Yilmaz O.H., Tothova Z., Joseph N.M., Lim M.S., Gilliland D.G., Morrison S.J. MTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell. Stem. Cell. 2010, 7:593-605.
91. Guo W., Schubbert S., Chen J.Y., Valamehr B., Mosessian S., Shi H., Dang N.H., Garcia C., Theodoro M.F., Varella-Garcia M., Wu H. Suppression of leukemia development caused by PTEN loss. Proc. Natl. Acad. Sci. USA 2011, 108:1409-1414.
92. Das F., Ghosh-Choudhury N., Dey N., Mandal C.C., Mahimainathan L., Kasinath B.S., Abboud H.E., Ghosh Choudhury G. Unrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt. J. Biol. Chem. 2011, (Epub ahead of print).
93. Zha X., Hu Z., He S., Wang F., Shen H., Zhang H. TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade. Cancer Lett. 2011, 313:211-217.